Phar­ma reps re­turn to doc­tors' of­fices, but dig­i­tal chan­nels re­main im­por­tant, new da­ta show

3 years ago
Pharma
Marketing

Mi­cro­cap biotech's shares crater on a PhI­II fail­ure for heavy drink­ing drug

3 years ago
R&D

FDA+ roundup: New draft guid­ance on ther­a­peu­tic equiv­a­lence; Cavaz­zoni talks ac­cel­er­at­ed ap­provals

3 years ago
FDA+

With­out vol­un­tary with­drawals, ODAC to re­view two more dan­gling ac­cel­er­at­ed ap­provals

3 years ago
R&D
FDA+

Armed with a $48M Se­ries A, Au­ron is look­ing to ap­ply ma­chine learn­ing in can­cer treat­ment

3 years ago
Financing
Startups

Scoop: Ab­b­Vie ter­mi­nates ear­ly-stage study of I-Mab's an­ti­body, an­oth­er clin­i­cal set­back in CD47 field

3 years ago
R&D
China

'Not in to­day's mar­ket': As Am­gen, Bris­tol My­ers back an­ti­body start­up BigHat, bear mar­ket keeps IPO win­dow shut ...

3 years ago
Financing
Startups

Rev­o­lu­tion Med­i­cines looks to raise $230M in new pub­lic of­fer­ing

3 years ago
Financing

Covid-19 roundup: No­vavax set to re­lease its first vac­cine batch in US; Switzer­land to buy over 1200 dos­es of ...

3 years ago
Coronavirus

F-star lines up Take­da pact weeks af­ter M&A ex­it; En route to Eu­rope de­ci­sion, Gen­Sight touts 5-year da­ta

3 years ago
News Briefing

Up­dat­ed: Small cannabi­noid biotech says its CMO was hit with cy­ber­at­tack, re­sult­ing in clin­i­cal tri­al de­lays

3 years ago
R&D

Bio­gen posts a sol­id quar­ter but chops drugs and qui­et­ly pays out $900M in le­gal set­tle­ment ahead of close­ly watched ...

3 years ago
Pharma

Keytru­da hit with sec­ond PhI­II set­back this year as Mer­ck­'s block­buster flops cer­tain head and neck tri­al

3 years ago
R&D

Bris­tol My­ers vets tie up an­oth­er all-stock deal, lin­ing up clin­i­cal-stage on­col­o­gy pipeline

3 years ago
Deals
R&D

Dai­ichi Sankyo los­es bid to bat back a $42M patent ver­dict over En­her­tu

3 years ago
Law

Ex­clu­sive: Mark Pruzan­s­ki is once again reach­ing for the brass ring in biotech

3 years ago
Startups
Bioregnum

Gene ther­a­py for ovar­i­an can­cer fails PhI­II study — sink­ing biotech's shares

3 years ago
R&D
Cell/Gene Tx

With a fresh $100M in hand, one RNA start­up is mov­ing to the clin­ic, find­ing part­ners and build­ing a new lab — all ...

3 years ago
Financing

No­var­tis scraps key PD-1 sub­mis­sion, while tout­ing 'sig­nif­i­cant bolt-on M&A fire­pow­er'

3 years ago
Pharma

J&J tones down M&A hype — down­shifts to 'neu­tral po­si­tion' while trim­ming sales guid­ance

3 years ago
Pharma

MD­MA psy­chother­a­py tri­al put on pause af­ter Health Cana­da in­spec­tion

3 years ago
R&D
FDA+

FDA slaps Im­prim­is­Rx with a warn­ing let­ter over spon­sored ar­ti­cles in med­ical jour­nals

3 years ago
Pharma
Marketing

Am­gen, GSK, Re­genxbio and oth­ers urge SCO­TUS to re­view 'dam­ag­ing' de­ci­sion on bio­med­ical patents

3 years ago
R&D
Law

Phar­ma's new 'Ber­lin De­c­la­ra­tion' seeks to re­serve vac­cines, ther­a­peu­tics in pro­duc­tion for low-in­come coun­tries

3 years ago
Coronavirus
First page Previous page 489490491492493494495 Next page Last page
A service from the Financial Times